Zani Marie-Louise, Nobar Shila M, Lacour Sandrine A, Lemoine Soazig, Boudier Christian, Bieth Joseph G, Moreau Thierry
INSERM U618, University François Rabelais, Tours, France.
Eur J Biochem. 2004 Jun;271(12):2370-8. doi: 10.1111/j.1432-1033.2004.04156.x.
Elafin and its precursor, trappin-2 or pre-elafin, are specific endogenous inhibitors of human neutrophil elastase and proteinase 3 but not of cathepsin G. Both inhibitors belong, together with secretory leukocyte protease inhibitor, to the chelonianin family of canonical protease inhibitors of serine proteases. A cDNA coding either elafin or its precursor, trappin-2, was fused in frame with yeast alpha-factor cDNA and expressed in the Pichia pastoris yeast expression system. Full-length elafin or full-length trappin-2 were secreted into the culture medium with high yield, indicating correct processing of the fusion proteins by the yeast KEX2 signal peptidase. Both recombinant inhibitors were purified to homogeneity from concentrated culture medium by one-step cationic exchange chromatography and characterized by N-terminal amino acid sequencing, Western blot and kinetic studies. Both recombinant elafin and trappin-2 were found to be fast-acting inhibitors of pancreatic elastase, neutrophil elastase and proteinase 3 with k(ass) values of 2-4 x 10(6) m(-1).s(-1), while dissociation rate constants k(diss) were found to be in the 10(-4) s(-1) range, indicating low reversibility of the complexes. The equilibrium dissociation constant K(i) for the interaction of both recombinant inhibitors with their target enzymes was either directly measured for pancreatic elastase or calculated from k(ass) and k(diss) values for neutrophil elastase and proteinase 3. K(i) values were found to be in the 10(-10) molar range and virtually identical for both inhibitors. Based on the kinetic parameters determined here, it may be concluded that both recombinant elafin and trappin-2 may act as potent anti-inflammatory molecules and may be of therapeutic potential in the treatment of various inflammatory lung diseases.
弹性蛋白原及其前体——捕弹肽-2或前弹性蛋白原,是人类中性粒细胞弹性蛋白酶和蛋白酶3的特异性内源性抑制剂,但不是组织蛋白酶G的抑制剂。这两种抑制剂与分泌型白细胞蛋白酶抑制剂一起,都属于丝氨酸蛋白酶的典型蛋白酶抑制剂的海龟宁家族。编码弹性蛋白原或其前体捕弹肽-2的cDNA与酵母α-因子cDNA进行读码框融合,并在毕赤酵母表达系统中表达。全长弹性蛋白原或全长捕弹肽-2以高产率分泌到培养基中,表明酵母KEX2信号肽酶对融合蛋白进行了正确加工。两种重组抑制剂通过一步阳离子交换色谱法从浓缩培养基中纯化至同质,并通过N端氨基酸测序、蛋白质印迹和动力学研究进行表征。发现重组弹性蛋白原和捕弹肽-2都是胰腺弹性蛋白酶、中性粒细胞弹性蛋白酶和蛋白酶3的快速作用抑制剂,其结合速率常数k(ass)值为2 - 4×10(6) m(-1)·s(-1),而解离速率常数k(diss)在10(-4) s(-1)范围内,表明复合物的可逆性较低。两种重组抑制剂与其靶酶相互作用的平衡解离常数K(i),对于胰腺弹性蛋白酶是直接测量的,对于中性粒细胞弹性蛋白酶和蛋白酶3则是根据k(ass)和k(diss)值计算得出的。发现K(i)值在10(-10)摩尔范围内,两种抑制剂实际上相同。根据此处测定的动力学参数,可以得出结论,重组弹性蛋白原和捕弹肽-2都可能作为有效的抗炎分子,在治疗各种炎症性肺病方面可能具有治疗潜力。